# Calcific Aortic Valve Disease: Mechanism and Future Therapeutic Strategies

## TL;DR

Calcific aortic valve disease involves active cellular and molecular processes that lead to valve calcification, and new therapeutic strategies may help delay or prevent the disease.

## Contribution

The paper identifies key molecular pathways and emerging therapeutic strategies for calcific aortic valve disease.

## Key findings

- CAVD is driven by endothelial dysfunction, inflammation, extracellular matrix remodeling, and osteogenic reprogramming.
- Molecular pathways like Notch, Wnt/β-catenin, BMP2, TGF-β, TNAP, and DPP-4 are central to valvular calcification.
- RNA-based therapeutics and enzyme inhibition are promising new treatment approaches.

## Abstract

What are the main findings?
Calcific aortic valve disease is an actively regulated process driven by endothelial dysfunction, inflammation, extracellular matrix remodeling, and osteogenic reprogramming of valvular interstitial cells.Key molecular pathways and enzymes, including Notch, Wnt/β-catenin, BMP2, TGF-β, TNAP, and DPP-4, play central roles in promoting valvular calcification and disease progression.

Calcific aortic valve disease is an actively regulated process driven by endothelial dysfunction, inflammation, extracellular matrix remodeling, and osteogenic reprogramming of valvular interstitial cells.

Key molecular pathways and enzymes, including Notch, Wnt/β-catenin, BMP2, TGF-β, TNAP, and DPP-4, play central roles in promoting valvular calcification and disease progression.

What are the implications of the main findings?
Understanding the molecular mechanisms of CAVD provides potential therapeutic targets for pharmacological intervention beyond valve replacement.Emerging strategies such as enzyme inhibition, RNA-based therapeutics, and targeted drug delivery may offer promising approaches to delay or prevent disease progression.

Understanding the molecular mechanisms of CAVD provides potential therapeutic targets for pharmacological intervention beyond valve replacement.

Emerging strategies such as enzyme inhibition, RNA-based therapeutics, and targeted drug delivery may offer promising approaches to delay or prevent disease progression.

Calcific aortic valve disease (CAVD) is an active pathological process driven by complex cellular and molecular mechanisms rather than passive aging. The disease is characterized by endothelial dysfunction, lipid infiltration, inflammation, extracellular matrix remodeling, and osteogenic differentiation of valvular interstitial cells, ultimately leading to hydroxyapatite deposition and progressive valve calcification. Key signaling pathways, including Notch, Wnt/β-catenin, BMP2, and TGF-β, play critical roles in osteogenic reprogramming, while inflammatory cytokines such as IL-6, IL-1β, and TNF-α contribute to a pro-calcific microenvironment. To summarize current knowledge on CAVD pathophysiology and emerging therapeutic strategies, relevant preclinical studies were identified through searches of PubMed, and clinical trials were identified through ClinicalTrials.gov. Evidence indicates that extracellular matrix remodeling, fibrosis, and dysregulated phosphate metabolism, particularly involving TNAP and DPP-4, further accelerate disease progression. Despite advances in understanding disease mechanisms, effective pharmacological therapies remain limited, with the current treatment largely restricted to valve replacement. Emerging therapeutic approaches targeting molecular pathways, including enzyme inhibition, RNA-based therapeutics, and advanced drug delivery systems, may offer promising strategies for disease modification. A deeper understanding of CAVD pathophysiology may facilitate the development of targeted therapies to delay or prevent disease progression.